Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i>In vivo</i> comparison of 2′‐<i>O</i>‐methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping

12 Jan 2009

Abstract excerpt

BACKGROUND: Antisense-mediated exon skipping is a putative treatment for Duchenne muscular dystrophy (DMD). Using antisense oligonucleotides (AONs), the disrupted DMD reading frame is restored, allowing generation of partially functional dystrophin and conversion of a severe Duchenne into a milder Becker muscular dystrophy phenotype. In vivo studies are mainly performed using 2'-O-methyl phosphorothioate (2OMePS)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Muscle Physiology and Disorders
Share to Telomeres, Telomerase, and Senescence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19140108
DOI: 10.1002/jgm.1288

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i>In vivo</i> comparison of 2′‐<i>O</i>‐methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skippingPMID 19140108Read ↗

Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse ModelsSemantic proximity Read ↗

Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse ModelSemantic proximity Read ↗

By‐passing the nonsense mutation in the 4<sup><i>CV</i></sup> mouse model of muscular dystrophy by induced exon skippingSemantic proximity Read ↗

Improved antisense oligonucleotide induced exon skipping in the <i>mdx</i> mouse model of muscular dystrophySemantic proximity Read ↗

Next steps for the optimization of exon therapy for Duchenne muscular dystrophySemantic proximity Read ↗

<i>DMD</i> antisense oligonucleotide mediated exon skipping efficiency is affected by flanking intron retention time and target position within the exonSemantic proximity Read ↗

Clinical trials of exon skipping in Duchenne muscular dystrophySemantic proximity Read ↗

Sequence determinants of efficient exon 44 skipping in Duchenne muscular dystrophy define design principles for steric-blocking antisense oligonucleotidesSemantic proximity Read ↗

RNA Therapeutics for Duchenne Muscular Dystrophy: Exon Skipping, RNA Editing, and Translational Insights from Genome-Edited Microminipig Models.Semantic proximity Read ↗

Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials.Semantic proximity Read ↗

Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges.Semantic proximity Read ↗

Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.